Microarray screening for novel preeclampsia biomarker candidates.
- Lapaire O Department of Obstetrics and Gynecology, University Hospital Basel, Basel, Switzerland. olapaire@uhbs.ch
- Grill S
- Lalevee S
- Kolla V
- Hösli I
- Hahn S
- 2012-04-05
Published in:
- Fetal diagnosis and therapy. - 2012
Adult
Analysis of Variance
Biomarkers
Case-Control Studies
Chorionic Gonadotropin, beta Subunit, Human
Chorionic Villi
Female
Gene Expression Profiling
Gene Expression Regulation
Genetic Markers
Humans
Luteinizing Hormone, beta Subunit
NADPH Oxidase 4
NADPH Oxidases
Oligonucleotide Array Sequence Analysis
Pre-Eclampsia
Pregnancy
Real-Time Polymerase Chain Reaction
Reproducibility of Results
Reverse Transcriptase Polymerase Chain Reaction
Serine Endopeptidases
Switzerland
Young Adult
English
INTRODUCTION
Our aim was to identify novel biomarker candidates for the near-term prediction of preeclampsia in a homogenous collective. In this study, we screened at the genome-wide level for gene expression in placental villous tissue from patients with severe preeclampsia in comparison to normal healthy pregnancies.
MATERIAL AND METHODS
Total RNA was extracted from placental villous tissue from 9 preeclamptic patients and 7 normotensive controls after scheduled cesarean sections. After sample pooling, gene expression analysis was performed using six Affymetrix Human Gene 1.0 ST arrays, followed by quantitative RT-PCR and validation of selected markers in the serum of patients at the protein level.
RESULTS
In total, 896 significantly differentially expressed genes were identified (p ≤ 0.05). After restricting these to molecules present in the circulation, 9 upregulated and 5 downregulated genes were selected. Four of them (β-hCG, HTRA4, LHB1, all upregulated; and NOX4, downregulated) were validated by quantitative real-time RT-PCR. Finally, the maternal plasma protein levels of 2 of these genes (LHB and β-hCG) were confirmed to be significantly different between preeclampsia cases and controls.
DISCUSSION
We identified 14 potential new biomarker candidates for preeclampsia and validated 4 of them by quantitative RT-PCR and 2 of them with subsequent serum protein analyses. Further studies will assess the optimal marker combination for the imminent prediction of impending preeclampsia.
Our aim was to identify novel biomarker candidates for the near-term prediction of preeclampsia in a homogenous collective. In this study, we screened at the genome-wide level for gene expression in placental villous tissue from patients with severe preeclampsia in comparison to normal healthy pregnancies.
MATERIAL AND METHODS
Total RNA was extracted from placental villous tissue from 9 preeclamptic patients and 7 normotensive controls after scheduled cesarean sections. After sample pooling, gene expression analysis was performed using six Affymetrix Human Gene 1.0 ST arrays, followed by quantitative RT-PCR and validation of selected markers in the serum of patients at the protein level.
RESULTS
In total, 896 significantly differentially expressed genes were identified (p ≤ 0.05). After restricting these to molecules present in the circulation, 9 upregulated and 5 downregulated genes were selected. Four of them (β-hCG, HTRA4, LHB1, all upregulated; and NOX4, downregulated) were validated by quantitative real-time RT-PCR. Finally, the maternal plasma protein levels of 2 of these genes (LHB and β-hCG) were confirmed to be significantly different between preeclampsia cases and controls.
DISCUSSION
We identified 14 potential new biomarker candidates for preeclampsia and validated 4 of them by quantitative RT-PCR and 2 of them with subsequent serum protein analyses. Further studies will assess the optimal marker combination for the imminent prediction of impending preeclampsia.
- Language
-
- English
- Open access status
- bronze
- Identifiers
-
- DOI 10.1159/000337325
- PMID 22472943
- Persistent URL
- https://sonar.ch/global/documents/205717
Statistics
Document views: 24
File downloads:
- Full-text: 0